downgrad neutral
messag partner sanofi report sale key product
consensu dupix miss earli launch disappoint could foreshadow
slower forecast ramp praluent kevzara growth also may acceler near-
term eylea could face new competit cemiplimab dupix asthma potenti
approv date oct make revenu contribut weight
move neutral rate remov pt previous buy-rat pt
base develop see greater pipelin progress assess fair
valu report result may
eylea sale report may competitor develop could remain
overhang report financi result thursday asid eylea
key product sale report partner sanofi sni apr forecast above-
consensu us eylea sale ex-u sale eylea growth
slow face potenti competit novarti nv brolucizuamb potenti
roch rhhbi potenti longer-act wet
drug beyond first highlight concern feb slippag
driver view made difficult counter
dupix could star role miss concern near-term
less visibl growth trend beyond partner sanofi report sale
us ex-u miss consensu neg
impact inventori drawdown patient assist program
inventori drawdown problemat sinc unexpect growth product earli
launch futur growth conting upon new indic occur later
consensu estim us ex-u could come
possibl outer year
cemiplimab could add anoth sale driver us initi approv could come
late partner sni announc cemiplimab file approv
eu us pdufa date oct cutan squamou cell carcinoma
consensu sale us ex-u even approv come
sooner initi indic target nich market competit bar nsclc
move believ
praluent kevzara growth remain uncertain least praluent sale
us ex-u consensu us ex-u
outcom data praluent posit less ideal base competitor
comment growth anticip data ad
label addit sny/ process payer discuss could
disrupt revenu net price move lower even market share increas consensu
model us ex-u sni report kevzara sale
miss consensu also unlik view growth driver
consensu model us ex-u
chang forecast downward lead cut pipelin hold potenti
upsid believ dupix growth sinc consensu look beatabl
label expans new product approv pipelin news flow could overcom eylea
praluent relat competitor develop miss slip timelin
necessit reassess led reduc product sale forecast dupix
praluent kevzara neutral rate assess fair valu share
believ much risk downsid upsid
one interest scientif platform biotech potenti deliv
upsid surpris emerg futur growth driver could lead us review forecast
page analyst certif import disclosur
eylea sale report may competitor develop could remain overhang report
financi result thursday asid eylea key product sale report partner sanofi sni
apr forecast us eylea sale ex-u sale consensu
respect competitor lucenti sold roch rhhbi us novarti nv outsid us post
strong sale respect highest sale total report past
year varianc expect possibl reflect market expans could
posit eylea consensu us sale ex-u sale eylea growth
slow face potenti competit novarti nv brolucizuamb potenti roch
rhhbi potenti longer-act wet drug beyond first
highlight concern feb slippag driver view made
difficult counter even timelin slippag brolucizuamb may fulli remov overhang unless
signific safeti differ emerg favor eylea brolucizumab someth expect current
approv everi month dose eylea could make play field level long two drug
candid appear larg similar risk eylea sale eros view
dupix could star role miss concern near-term less visibl growth
trend beyond partner sanofi report sale us ex-u miss
consensu neg impact inventori drawdown patient assist
program inventori drawdown problemat sinc unexpect growth product earli
launch us weekli prescript data show better growth vs prior quarter
sni also report nbrx weekli transit seriou
moderate-to-sever patient futur growth conting upon new market reimburs eu
countri new patient age group new indic occur either later
consensu estim us ex-u us ex-u
could come possibl outer year
cemiplimab ad anoth sale driver us approv could later bar success
move partner sni announc cemiplimab file approv eu us pdufa date
oct cutan squamou cell carcinoma consensu sale us ex-u
also unusu file typic happen us first sni ask challeng
file impli none cemiplimab data btd design us data
come checkpoint inhibitor market competit initi indic cutan
squamou cell carcinoma basal cell carcinoma could limit market opportun vs bigger market
like non-smal cell lung cancer bar success lung cancer also gone merck keytruda
consid clear leader data beat consensu estim may come cemiplimab
praluent kevzara growth remain uncertain least praluent sale us ex-u
consensu us ex-u outcom data praluent posit less
page analyst certif import disclosur
ideal base competitor comment growth anticip data ad
label repatha sale increas outcom data present also coincid legal
decis rais question around likelihood praluent abl stay market praluent weekli trx
growth though quarter date addit sny/ process payer
discuss greater access net price like closer per patient per year could disrupt revenu
sinc potenti trade net price decreas market share increas given
dynam expect competit includ mdco inclisiran studi praluent unlik
given credit growth driver consensu model us ex-u kevzara trx
growth quarter date base still small dollar term sni report
kevzara sale miss consensu also unlik view growth driver consensu
model us ex-u therefor consensu estim could come praluent
kevzara
pipelin still news flow pend broad could becom futur driver one
interest scientif platform pipelin biotech come expect big thing howev
number new product data readout meaning may occur asid fda decis
everi month dose eylea due aug dupilumab pdufa date moderate-to-sever
asthma oct dupilumab data nasal polyposi atop dermat pediatr cemiplimab
pivot data basal cell carcinoma potenti approv cemiplimab us earli
fasinumab data hip/ knee osteoarthr pain could updat radar
program investor given potenti advers event could regulatori support sinc least
partial solut opioid earli stage readout could includ data cancer praluent label could
expand includ outcom data long-term program pipelin especi evinacumab
potenti advanc quickli and/ synergist regn exist franchis infrastructur
chang forecast reduct revenu neutral rate fair valu assess per share
believ dupix growth sinc consensu look beatabl label expans
cemiplimab bla file pipelin news flow could overcom eylea praluent competitor
develop miss slip timelin base expect plu emerg competitor
newer competitor data necessit reassess project led reduct forecast
product sale ep increas discount rate develop stage product candid us
govern focu drug price potenti chang part program includ re-emerg
medicar pilot program assess practic impact could also creat short-term overhang
fair valu per share though risk remain arriv fair valu assess use product level dcf
impact reduc revenu forecast increas discount rate develop stage
candid well price-to-earnings base multipl index year ep reduc per share
combin still result fair valu assess risk remain even though potenti
upsid current level fair valu estim believ much downsid risk
dupix main driver stock could continu disappoint consensu could continu come
page analyst certif import disclosur
guggenheim sale estim vs consensu praluent outcom data may translat
increas sale consensu indic guggenheim sale estim vs consensu
cemiplimab may meaning contributor top-lin sinc initi indic could limit
bigger indic non-smal cell lung cancer see approv competitor data could move
bar higher pipelin news flow eylea secur everi month approv may prove insuffici
catalyst averag price-to-earnings multipl larg cap biotech earn trade
consensu ep averag sale base multipl trade emerg futur growth driver
could lead us review forecast
page analyst certif import disclosur
page analyst certif import disclosur
product eylea eylea ex-u praluent praluent ex-u cemiplimab cemiplimab ex-u dupix dupix ex-u sarilumab sarilumab ex-u good collabor contract tax net non weight averag share outstand ep figur calcul use basic sharessourc report factset guggenheim secur llc estim
page analyst certif import disclosur
 net product reimburs commercialization-rel unreimburs unreimburs non-cash share-bas compens non-cash share-bas compens tax report guggenheim secur llc estimatesinflammatoryexpect news flowtimingdupixentfil asthma eosinophil data asthma data nasal approv oct patient moder dupixentiniti data nasal pediatr ad age studi food studi co-morbid data atop dermat pediatr approv nasal data atop dermat approv pediatr ad age data moder sever data children uncontrol data atop dermat infant news flowtim competitor detail wet top-lin feb competitor detail wet feb dose sblaaug data dr sbla diabet retinopathi pre-fil data
page analyst certif import disclosur
oncologyexpect news flowtimingcemiplimabfil bla cscc accept interim data initi vs data approv cutan squamou cell data cancer anti-tgfbeta /- data cancer data renal data nhl cll data lymphoma data cervic data advanc caner isatuximab data nsclc line vs plat news flowtimingpraluentfil sbla outcom bempedo data use apheresisaug hofh expans reflect outcom data data persist data patient news data hip/kne osteoarthr pain long-term data hip/kne osteoarthr pain vs data hip/kne osteoarthr pain vs data chronic low back pain hip/kne oa news data data giant cell polymyaigia news studi healthi autoimmun neurosensori hear /- studi healthi studi muscl allergi next healthi volunt ebola viru cocktail next candidatesadv clinic data fibrodysplasia ossifican report guggenheim secur llc estimatesnot denot potenti catalyt event
page analyst certif import disclosur
